Researchers have identified 27 biomarkers that could be used to predict the course of SARS-CoV-2 infection and whether a patient with COVID-19 will become severely ill.
List view / Grid view
Filter the results
Sergio Traversa, PharmD, from Relmada Therapeutics explains why NMDA antagonists may provide an answer for patients who do not respond to current antidepressant therapies.
Researchers have used a specific chemical signal released from a major bacterial pathogen to improve the activity of fluconazole against Candida biofilms.
A polio vaccine designed to be incapable of evolving the ability to cause disease in humans has shown promise in a Phase I clinical trial.
The US National Institute of Allergy and Infectious Diseases (NIAID) has revealed its research priorities relating to COVID-19, including supporting the development and testing of potential therapeutics and vaccines.
Professor Saad Shakir explains why cytokine storms occur in COVID-19 patients and suggests potential therapies for the symptoms of the coronavirus.
The UK MHRA granted expedited acceptance for the Phase II trial of MRx-4DP0004, a live biotherapy product and targeted immunomodulatory therapy.
A new report has revealed the vaccine R&D efforts of 15 of the leading pharmaceutical companies to combat the COVID-19 coronavirus.
The US FDA has announced that all manufacturers should withdraw their ranitidine products from the market due to the risks associated with NDMA impurities.
Using AAV-based technology to deliver mAbs in a Phase I trial, researchers report that participants successfully developed antibodies against HIV.
European Pharmaceutical Review rounds up the latest news surrounding COVID-19, including a vaccine moving to clinical trials and the FDA's update on Chinese import inspections.
Researchers have created targeted, modifiable nanoparticles which could be combined with pharmaceuticals as a form of drug delivery to treat cancer.
The US Food and Drug Administration (FDA) has granted Priority Review for capmatinib, a treatment for MET exon 14 skipping mutated non-small cell lung cancer.
Researchers at Aston University and Birmingham Children’s Hospital, UK, have discovered a highly effective three-drug approach to treat Mycobacterium abscessus (M. abscessus), a notoriously drug-resistant pathogen that affects up to 13 percent of cystic fibrosis (CF) patients in the UK.
The first US in-human trial of CRISPR-Cas9-edited T cells has concluded with no ill effects and showed that nine months later the infused cells were still active against cancer.